CliffBio
small molecule

OBREDON

GUAIFENESIN; HYDROCODONE BITARTRATE

Loss of exclusivityNovember 2035latest FDA-listed patent expiry
CompanySovereign Labs →See this company's full patent-cliff portfolio

Drug detail

Brand nameOBREDON
Active ingredientGUAIFENESIN; HYDROCODONE BITARTRATE
Strength200MG/5ML;2.5MG/5ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2014
Marketing statusDISCN

Listed patents

PatentExpiresType
9549907November 2035substance, product
9808431November 2035substance, product
10105324November 2035substance, product

More from Sovereign Labs

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.